Adaptimmune Therapeutics Plc - notizie pubblicate 224 - letture 5.568
ADAPTIMMUNE THERAPEUTICS PLC
Transcript Q2 2024
Adaptimmune therapeutics second quarter 2024 conference call transcript date: monday, august 12th, 2024 time: 8:00 am et / 5:00 am pt presenters: dan od-cohen investor relations ad ...
ADAPTIMMUNE THERAPEUTICS PLC
10-Q Filing Q2 2024
Table of contents united states securities and exchange commission washington, d.c. 20549 form 10-q quarterly report pursuant to section 13 or 15(d) of the securities exchange act ...
ADAPTIMMUNE THERAPEUTICS PLC
Quarterly Report for Quarter Ending June 30, 2024 (Form 10-Q)
Table of contents united states securities and exchange commission washington, d.c. 20549 form 10-q ☒ quarterly report pursuant to section 13 or 15(d) of the securities exchange ...
ADAPTIMMUNE THERAPEUTICS PLC
Earnings Release Q2 2024
August 12, 2024 adaptimmune reports q2 2024 financial and business updates adaptimmune received u.s. fda accelerated approval of tecelra® (afami-cel), the first approved engineere ...
ADAPTIMMUNE THERAPEUTICS PLC
Adaptimmune Reports Q2 2024 Financial and Business Updates Form 8 K
Adaptimmune reports q2 2024 financial and business updates adaptimmune received u.s. fda accelerated approval of tecelra® (afami-cel), the first approved engineered cell therapy f ...
ADAPTIMMUNE THERAPEUTICS PLC
Adaptimmune Reports Q2 2024 Financial and Business Updates
August 12, 2024 adaptimmune reports q2 2024 financial and business updates adaptimmune received u.s. fda accelerated approval of tecelra® (afami-cel), the first approved engineere ...
ADAPTIMMUNE THERAPEUTICS PLC
Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024
August 5, 2024 adaptimmune to report q2 2024 financial and business updates on monday, august 12, 2024 philadelphia, pennsylvania and oxford, united kingdom--(newsfile corp. - augu ...
ADAPTIMMUNE THERAPEUTICS PLC
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor Form 8 K
Adaptimmune receives u.s. fda accelerated approval of tecelra® (afamitresgene autoleucel), the first approved engineered cell therapy for a solid tumor approved for advanced mage- ...
ADAPTIMMUNE THERAPEUTICS PLC
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
August 1, 2024 adaptimmune receives u.s. fda accelerated approval of tecelra® (afamitresgene autoleucel), the first approved engineered cell therapy for a solid tumor approved for ...
ADAPTIMMUNE THERAPEUTICS PLC
Management Change/Compensation Form 8 K
Item 5.02 departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers. on july 16, 2024, adapt ...
ADAPTIMMUNE THERAPEUTICS PLC
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ADAPTIMMUNE THERAPEUTICS PLC
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ADAPTIMMUNE THERAPEUTICS PLC
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ADAPTIMMUNE THERAPEUTICS PLC
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ADAPTIMMUNE THERAPEUTICS PLC
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti